National Joint Registry

National Joint Registry
Name	National Joint Registry
Formation	2003
Type	Registry
Headquarters	United Kingdom
Region served	England and Wales; Northern Ireland; Scotland
Leader title	Chief Executive

National Joint Registry

The National Joint Registry (NJR) is a UK-based clinical registry established to record joint replacement operations and monitor performance across hospitals, trusts, and device manufacturers. It aggregates procedural and implant-level data to support regulators, clinicians, manufacturers, and patients across institutions such as National Health Service (England and Wales), NHS Scotland, and Health and Social Care in Northern Ireland while interfacing with international bodies including Australian Orthopaedic Association National Joint Replacement Registry, American Joint Replacement Registry, and European Arthroplasty Register.

History

The inception of the NJR followed high-profile implant failures and regulatory responses in the late 20th and early 21st centuries, including inquiries related to devices used in hip replacement and knee replacement surgery. Its formation in 2003 was influenced by reports from Cumberlege Inquiry advocates, recommendations from Department of Health and Social Care (United Kingdom), and stakeholders from the British Orthopaedic Association, Royal College of Surgeons of England, and Royal College of Surgeons of Edinburgh. Early data linkage efforts drew on experience from registries like the Swedish Hip Arthroplasty Register and methodology from the National Joint Registry for England and Wales predecessor initiatives. Over successive annual reports, the NJR expanded coverage to include patient-reported outcome measures, revisions surveillance, and device performance benchmarking used by the Medicines and Healthcare products Regulatory Agency.

Purpose and scope

The NJR’s stated purpose is to collect comprehensive information on joint replacement procedures — principally total hip replacement, total knee replacement, and shoulder arthroplasty — to improve patient safety, inform purchasing decisions, and guide clinical practice. Its scope covers implants, surgical technique, surgeon and hospital identifiers, and revision rates, and extends to collaborative projects with entities such as National Institute for Health and Care Excellence, Health Quality Improvement Partnership, and commercial suppliers like Stryker Corporation, DePuy Synthes, and Zimmer Biomet. The registry supports surveillance of novel devices introduced after CE marking or CE Mark processes, and contributes to post-market surveillance and device recall processes alongside the European Medicines Agency and international orthopaedic bodies.

Data collection and methodology

Data collection is performed through mandated and voluntary submissions from healthcare providers across England, Wales, Scotland, and Northern Ireland. The NJR captures procedure-level fields including patient demographics, indication for surgery (e.g., osteoarthritis, rheumatoid arthritis), implant catalogue identifiers, fixation methods, and operative dates. Methodological approaches include deterministic and probabilistic linkage with national datasets such as the Office for National Statistics, Hospital Episode Statistics, and mortality records. The registry employs survival analysis, Kaplan–Meier estimates, and Cox proportional hazards modelling to assess implant longevity and risk factors, and integrates patient-reported outcome measures comparable to instruments used by EuroQol Group and Oxford Hip Score initiatives. Quality assurance processes invoke audit trails, data validation against procurement records, and device batch-trace checks with manufacturers including Smith & Nephew.

Governance and funding

Governance structures involve a board comprised of representatives from professional organisations such as the British Orthopaedic Association, patient groups like Arthritis Research UK, and regulatory observers from the Care Quality Commission. Operational oversight is provided by an executive supported by academic partners at institutions including Imperial College London, University of Oxford, and University of Bristol for methodological expertise. Funding is a mixture of grant support, contractual payments from the Department of Health and Social Care (United Kingdom), subscription fees from participating organisations, and industry contributions under managed access agreements with manufacturers such as Zimmer Biomet Holdings, Inc. and DePuy Synthes (Johnson & Johnson). Ethical oversight and data governance adhere to frameworks from Health Research Authority and data protection principles influenced by Data Protection Act 2018.

Key findings and impact on clinical practice

The NJR has produced high-profile findings influencing practice, such as differential survivorship between bearing surfaces in hip arthroplasty, higher revision rates for specific metal-on-metal implants, and performance variations among implant brands used in total knee replacement. These outputs prompted recalls, label changes, and changes in national procurement strategies informed by reports to bodies like the Medicines and Healthcare products Regulatory Agency and policy makers at the Department of Health and Social Care (United Kingdom). The registry’s benchmarking has supported surgeon-level audit, hospital performance reviews conducted by Care Quality Commission, and guideline updates from National Institute for Health and Care Excellence that affect implant selection, cemented versus uncemented fixation choices, and surveillance pathways for at-risk cohorts.

Criticisms and limitations

Criticisms include variable completeness and accuracy of some data fields, time lags between data submission and public reporting, and challenges in attributing causality from observational registry analyses — issues discussed in forums including the British Medical Journal and conferences hosted by International Society of Arthroplasty Registries. Data linkage constraints, under-reporting of revisions performed outside initial centres, and limited capture of long-term patient-reported outcomes have been cited by academics at University of Manchester and patient advocates. Questions about industry funding and potential conflicts of interest have prompted calls for transparent governance reforms similar to those debated in reviews by the House of Commons Health Select Committee.

Category:Medical registries